
Uma Mahadevan
University of California san francisco
Dr. Uma Mahadevan is the Lynne and Marc Benioff Professor of Gastroenterology, Director of the Colitis and Crohn's Disease Center and Director of the Advanced IBD Fellowship at the University of California, San Francisco. She specializes in inflammatory bowel disease (IBD), particularly pregnancy and drug safety. She completed a medical degree at the State University of New York in Brooklyn, residency in internal medicine at Mount Sinai Medical Center in New York, Fellowship in gastroenterology at UCSF, and Advanced fellowship in IBD at the Mayo Clinic, Rochester, Minnesota. For her exceptional work in pregnancy and drug safety and her mentoring of GI fellows and junior faculty she received the AGA 2022 Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section Research Mentor Award and the 2022 Sherman Prize. Dr. Mahadevan is a fellow of the American Gastroenterological Association, for whom she was Chair for the IMIBD Section, Chair of the AGA National IBD Parenthood initiative and Director (2023) and co-Director (2022, 2017) of the AGA Postgraduate Course. She is a Fellow of the American College of Gastroenterology and served on the Educational Affairs Committee and as a member of the Advanced IBD Fellow Curriculum Committee. She was Chair of the Crohns Colitis Foundation Clinical Research Grants committee, a member of the National Scientific Advisory Committee and Taskforce on Women in IBD, and co-chair of the annual Crohn’s Colitis Congress (2020). Dr. Mahadevan is a member of the International Organization of IBD (IOIBD) for which she serves on the nominating committee. Dr. Mahadevan has served on many prestigious journals, including special section editor for Gastroenterology. Dr. Mahadevan has published over 100 original articles, abstracts, editorials, and invited reviews in such peer-reviewed journals as Gastroenterology, Gut, Nature Reviews, American Journal of Gastroenterology, Inflammatory Bowel Diseases, and Lancet Gastroenterology Hepatology as well as several book chapters. She authored the joint AGA, Society of Maternal Fetal Medicine Clinical Care Pathway on the Management of IBD in Pregnancy. Dr. Mahadevan is a global expert on the management of pregnancy and drug safety in the patient with IBD. She is also interested in the role of diet and IBD and has an ongoing original study in this area. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO) and a clinical trial on the impact of nutritional interventions in the management of IBD (SEAMUS). She has an interest in digital health and lead the transition of the GI Division to telemedicine at the start of the pandemic in March 2020 and has developed an IBD Chatbot with the Center for Digital Health and Innovation at UCSF. Dr. Mahadevan is proud to have mentored several Advanced IBD Fellows who know hold key roles in IBD Centers around the United States.
Appearances
- DateMay 7, 2023In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis…
Presenter
University of California san francisco - DateMay 7, 2023In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis…
Presenters
Mayo ClinicUniversity of California san franciscoMayo Foundation for Medical Education and ResearchMassachusetts General Hospital - DateMay 6, 2023
Moderators
University of California san franciscoMayo Clinic, RochesterUT Southwestern Medical Center - DateMay 6, 2023
Presenters
University of California san franciscoUniversity of Michigan - DateMay 8, 2023BACKGROUND: Mesenteric fat is increasingly believed to exert an important influence on intestinal inflammation. A hallmark of severe Crohn's disease (CD) is the accumulation of mesenteric fat around the inflamed intestine, typically in the terminal ileum…
Presenter
Speakers
University of California, San FranciscoUniversity of California san franciscoUniversity of California, San Francisco INFLAMMATORY BOWEL DISEASE AND THE RISK OF ANAL DYSPLASIA AND CANCER AMONG MEN WHO HAVE SEX WITH MEN
DateMay 8, 2023BACKGROUND: The impact of pregnancy on vedolizumab (VDZ) and ustekinumab (UST) pharmacokinetics is not well defined. Similarly, the time to infant clearance and outcomes following in-utero exposure require elucidation…Presenter
University of California San FranciscoSpeakers
- DateMay 7, 2023SOCIETY: AGA
Moderators
University of California san franciscoCedars-Sinai Medical Center - DateMay 18, 2024
Presenters
University of California san franciscoUniversity of North Carolina School of Medicine - DateMay 18, 2024
Presenters
University of California san franciscoUniversity of North Carolina School of MedicineUniversity of Chicago Division of the Biological Sciences - DateMay 19, 2024SOCIETY: AGA There is fear surrounding the impact of IBD and its therapies on pregnancy and infant outcomes, as well as fear surrounding the impact of pregnancy on IBD and maternal health…
Moderators
University of California san franciscoUniversity of North Carolina - DateMay 20, 2024Background: Women with inflammatory bowel disease (IBD) face the complexities of disease management during pregnancy and childbirth. Apprehension regarding vaginal delivery in pregnant individuals with IBD persists due to concern for perianal disease and perineal trauma…
Presenter
University of California, San FranciscoSpeakers
University of North CarolinaThe University of ChicagoUniversity of California san francisco - DateMay 20, 2024BACKGROUND: Pregnant women with ulcerative colitis (UC) have a higher risk of adverse pregnancy outcomes vs age-matched controls.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of UC. There are no well-controlled studies on tofacitinib use in pregnant women…
Presenter
University of California san franciscoSpeakers
Icahn School of Medicine, Mount Sinai - DateMay 19, 2024SOCIETY: AGA By popular demand, this new session highlights the best late-breakers submitted to the IBD section and well as innovations in technology and new paradigms of care in IBD
Moderators
University of California san franciscoUniversity of Chicago Division of the Biological Sciences - DateMay 4, 2025The landscape of treatment for IBD has evolved significantly over the past two decades. This session will examine advances in our understanding of disease pathogenesis and review treatment paradigm changes…
Moderators
University of California san franciscoNorthwestern Feinberg School of Medicine - DateMay 5, 2025This session will examine state of the art pivotal trials on efficacy of various biologic therapies for management of IBD…
Moderators
University of California san franciscoUNC Chapel Hill